Navigation Links
Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
Date:12/20/2010

TARRYTOWN, N.Y., Dec. 20, 2010 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time on Monday, December 20, to discuss results of the Phase 3 COPERNICUS study with VEGF Trap-Eye in central retinal vein occlusion (CRVO) and the week 52 follow-up results of the Phase 2 DA VINCI study in patients with diabetic macular edema (DME).  A press release will be issued prior to the call.

Teleconference/Webcast Details To participate in the live call on Monday, December 20, at 8:30 a.m. Eastern Time, please dial (877) 390-5538 for domestic callers and (408) 940-3843 for international callers, participant code 33105543.  The live conference call is being webcast and it can be accessed on the "Newsroom" page of the Company's web site, www.regeneron.com.  The webcast will be available for 30 days following the call.About Regeneron PharmaceuticalsRegeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com. Contact Information:Michael Aberman, M.D.

Peter DworkinInvestor Relations

Corporate Communications914.345.7799

914.345.7640michael.aberman@regeneron.com

peter.dworkin@regeneron.com
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Christine A. Poon Elected to Regeneron Board of Directors
2. Regeneron Announces Presentation at the 2010 Credit Suisse Annual Healthcare Conference
3. Regeneron Announces Presentation at the 17th Annual NewsMakers in the Biotech Industry Conference
4. Regeneron Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
5. Regeneron Increases Size of Public Offering of Common Stock
6. Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
7. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
8. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
11. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , February 5, 2016 Site ... Today, VoicePower Ltd - The Speech Recognition People, announced their latest ... to improve patient care, reduce turnaround times and to save the ... ,- VoicePower client since 2013 Challenge: --> ... --> - Six doctors ,- Wirral CCG ,- VoicePower ...
(Date:2/4/2016)... , Feb. 4, 2016  Edwards Lifesciences Corporation (NYSE: ... for structural heart disease and critical care monitoring, announced ... repurchase (ASR) agreement with Morgan Stanley & Co. LLC ... repurchase is part of the Company,s previously authorized program ... common stock.  --> ...
(Date:2/4/2016)... , Feb. 4, 2016  SciClone Pharmaceuticals, Inc. ... it has entered into a settlement agreement with ... fully resolving the SEC,s investigation into possible violations ... the terms of the settlement agreement, SciClone has ... including disgorgement, pre-judgment interest and a penalty.  This ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, ... services in their Napa Valley office. The technique utilizes the body’s own healing ... Canales and Dr. Furnas, are part of only a select few cosmetic surgeons ...
(Date:2/5/2016)... ... ... US Sports Camps , official operators of Nike Yoga Camps, announces ... training. ChildLight Yoga Studio is centrally situated in the picturesque New England city of ... founder Lisa Flynn expresses her excitement, “We are thrilled to be partnering with US ...
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one of ... for this weekend’s Big Game. Take the stress out of your party preparation – ... guests happy at every stage of the game. , “The key to hosting a ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... CitiDent, announces that it is now welcoming orthodontist, Dr. Amanda Cheng, to ... a complete range of oral health care, including general dentistry, cosmetic treatments, periodontics, ...
(Date:2/5/2016)... ... February 05, 2016 , ... On June 9-10, Las ... continuing medical education (CME) event presented by the Association for Comprehensive Care in ... for ACCORD, whose mission is to provide education, tools, and resources to primary ...
Breaking Medicine News(10 mins):